Zenas Biopharma Inc’s recent filing unveils that its Chief Executive Officer MOULDER LEON O JR acquired Company’s shares for reported $0.45 million on Dec 04 ’24. In the deal valued at $9.98 per share,45,000 shares were bought. As a result of this transaction, MOULDER LEON O JR now holds 241,155 shares worth roughly $2.29 million.
Then, MOULDER LEON O JR bought 25,000 shares, generating $269,000 in total proceeds. Upon buying the shares at $10.76, the Chief Executive Officer now owns 196,155 shares.
Before that, MOULDER LEON O JR bought 7,500 shares. Zenas Biopharma Inc shares valued at $112,500 were divested by the Chief Executive Officer at a price of $15.00 per share. As a result of the transaction, MOULDER LEON O JR now holds 168,655 shares, worth roughly $1.6 million.
Rodman & Renshaw initiated its Zenas Biopharma Inc [ZBIO] rating to a Buy in a research note published on November 05, 2024; the price target was $34. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in early October with a ‘”an Overweight”‘ rating. Jefferies began covering ZBIO with “Buy” recommendation on October 08, 2024. Guggenheim started covering the stock on October 08, 2024. It rated ZBIO as “a Buy”.
Price Performance Review of ZBIO
On Tuesday, Zenas Biopharma Inc [NASDAQ:ZBIO] saw its stock fall -5.19% to $9.50. Over the last five days, the stock has lost -11.46%. Zenas Biopharma Inc shares have fallen nearly -47.66% since the year began.
Levels Of Support And Resistance For ZBIO Stock
The 24-hour chart illustrates a support level at 8.85, which if violated will result in even more drops to 8.21. On the upside, there is a resistance level at 10.18. A further resistance level may holdings at 10.86. The Relative Strength Index (RSI) on the 14-day chart is 27.90, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.84, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.26%. Stochastics %K at 12.26% indicates the stock is a buying.
How much short interest is there in Zenas Biopharma Inc?
A steep rise in short interest was recorded in Zenas Biopharma Inc stocks on 2024-11-29, growing by 0.83 million shares to a total of 1.47 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 0.64 million shares. There was a rise of 56.76%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 08, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
